Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Michael Thorpy"'
Autor:
Ashley J. Malin, Sonali Bose, Stefanie A. Busgang, Chris Gennings, Michael Thorpy, Robert O. Wright, Rosalind J. Wright, Manish Arora
Publikováno v:
Environmental Health, Vol 18, Iss 1, Pp 1-9 (2019)
Abstract Background Fluoride from environmental sources accumulates preferentially in the pineal gland which produces melatonin, the hormone that regulates the sleep-wake cycle. However, the effects of fluoride on sleep regulation remain unknown. Thi
Externí odkaz:
https://doaj.org/article/9e781794e8ea4e648712f37987411a06
Publikováno v:
Monday, April 24.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::01348aa9237cc978e5c9b7fde1c17b41
https://doi.org/10.1212/wnl.0000000000202310
https://doi.org/10.1212/wnl.0000000000202310
Publikováno v:
SLEEP. 46:A252-A253
Introduction In the phase 3 REST-ON trial (NCT02720744), participants with narcolepsy type 1 (NT1) treated with once-nightly sodium oxybate (ON-SXB; FT218), an investigational, extended-release formulation, had significant reductions in cataplexy epi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1328f7ebf5033642ec4f2a4e700ca2b0
https://doi.org/10.1093/sleep/zsad077.0575
https://doi.org/10.1093/sleep/zsad077.0575
Publikováno v:
SLEEP. 46:A266-A266
Introduction In the phase 3 REST-ON trial (NCT02720744), mean sleep latency on the Maintenance of Wakefulness Test (MWT) was significantly improved vs placebo with investigational, extended-release once-nightly sodium oxybate (FT218 [ON-SXB]; P< 0.00
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f42fcac6a716225ab0a872066da6f584
https://doi.org/10.1093/sleep/zsad077.0607
https://doi.org/10.1093/sleep/zsad077.0607
Autor:
Thomas Stern, Bruce Corser, Richard Bogan, Jennifer Franco, Eric Konofal, George Apostol, Russell Rosenberg, Anne Morse, Michael Thorpy, Clete Kushida
Publikováno v:
SLEEP. 46:A261-A261
Introduction Mazindol ER (extended-release), the first partial orexin-2 receptor agonist and triple mono-aminergic reuptake inhibitor, has demonstrated efficacy and safety in significantly reducing excessive daytime sleepiness (EDS) and cataplexy att
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b24669882cbdf244d1a41cd40f153262
https://doi.org/10.1093/sleep/zsad077.0595
https://doi.org/10.1093/sleep/zsad077.0595
Autor:
Thomas Roth, Michael Thorpy, Clete Kushida, Anne Morse, Jordan Dubow, Jennifer Gudeman, Yves Dauvilliers
Publikováno v:
SLEEP. 46:A252-A252
Introduction Once-nightly sodium oxybate (ON-SXB; FT218), an investigational, extended-release treatment, was evaluated for the treatment of narcolepsy in adults in the phase 3 REST-ON clinical trial (NCT02720744). The 3 co-primary endpoints, mean sl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4fb304e641e0c3f0e6137b6ca461e175
https://doi.org/10.1093/sleep/zsad077.0573
https://doi.org/10.1093/sleep/zsad077.0573
Autor:
Richard Bogan, Thomas Stern, Bruce Corser, Jennifer Franco, Eric Konofal, George Apostol, Anne Morse, Russell Rosenberg, Michael Thorpy, Clete Kushida
Publikováno v:
SLEEP. 46:A260-A260
Introduction Efficacy secondary outcome measure Functional Outcomes of Sleep Questionnaire, Short Version (FOSQ-10] was collected in the Phase 2 (POLARIS, NLS-1021), multicenter (n=21) study of mazindol ER in adult participants with narcolepsy type 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bb7f372a351655db9e6e86858e1cdbbf
https://doi.org/10.1093/sleep/zsad077.0593
https://doi.org/10.1093/sleep/zsad077.0593
Autor:
Richard Bogan, Thomas Stern, Bruce Corser, Jennifer Franco, Eric Konofal, George Apostol, Anne Morse, Clete Kushida, Michael Thorpy, Russell Rosenberg
Publikováno v:
SLEEP. 46:A254-A254
Introduction Mazindol is the first partial orexin 2 receptor agonist and triple monoamine reuptake inhibitor in development for the treatment of narcolepsy. Clinician and Patient Global Impression (CGI and PGI, respectively) for cataplexy and excessi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0e2b3de3647b2c8b4f531732f26c81bf
https://doi.org/10.1093/sleep/zsad077.0578
https://doi.org/10.1093/sleep/zsad077.0578
Autor:
Bruce Corser, Thomas Stern, Richard Bogan, Jennifer Franco, George Apostol, Eric Konofal, Anne Morse, Russell Rosenberg, Clete Kushida, Michael Thorpy
Publikováno v:
SLEEP. 46:A257-A257
Introduction Mazindol is the first partial orexin 2 receptor agonist and triple monoamine reuptake inhibitor in development for the treatment of narcolepsy. A novel extended release (ER) formulation was developed to allow once-daily dosing and may pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d1255dedb3c4db8c435e7a1cbd929534
https://doi.org/10.1093/sleep/zsad077.0585
https://doi.org/10.1093/sleep/zsad077.0585
Autor:
JOHN WINKELMAN, MAURICE OHAYON, MICHAEL THORPY, DAVID SEIDEN, RICHARD BOGAN, JORDAN DUBOW, COLIN SHAPIRO
Publikováno v:
Chest. 160:A2426-A2428
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::08c420250de1001f9534bc62675b2e07
https://doi.org/10.1016/j.chest.2021.07.2097
https://doi.org/10.1016/j.chest.2021.07.2097